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Abstract
Background: Breast cancer remains the leading reason of  cancer death among women worldwide, and gefitinib is the effi-
cient drug for breast cancer. 
Aims: To use targeted metabolomics method to elucidate the therapeutic mechanism of  gefitinib through profiling the 
amino acids. 
Methods: Healthy women (n=56) and women with breast cancer (n=60) were enrolled in Affiliated Yuhuangding hospital, 
medical college of  Qingdao University from 2012-2014.  API 3200 triple quadrupole mass spectrometer was used to analyze 
the serum samples. 
Results: The concentration of   amino acids was compared between healthy women and women with breast cancers. Com-
pared with the healthy women, the concentration of  arginine in breast cancer women significantly decreased (p<0.0001). To 
show the representative capability of   arginine towards the pathogenesis of  breast cancers, the  receiver operating charac-
teristic (ROC) curve was drawn, and the area under the curve (AUC) was calculated to be  0.96 ± 0.02, indicating the high 
predictive capability of  arginine for breast cancer . The reversing ability of  gefitinib towards the level of  arginine was further 
determined, and 1 month treatment of  gefitinib (500 mg/day) significantly reversed the arginine level of  breast cancer pa-
tients (p<0.0001) 
Conclusion: The therapy of  gefitinib towards breast cancer through reversing breast cancer biomarker arginine was demon-
strated.
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Introduction
Breast cancer remains the leading reason of  cancer death 
among women worldwide1.  There are many risk factors 
for breast cancers, such as obesity, lack of  physical exer-
cise, and drinking alcohol. Many drugs have been used, 
are being developed, or exert the therapeutic potential 
towards breast cancers, such as paclitaxel, doxorubicin, 
fluorouracil, Everolimus, and anastrozole(http://www.
cancer.gov/cancertopics/druginfo/breastcancer). 
Gefitinib, under the trade name Iressa, marketed by As-
traZeneca and Teva, is a drug employed to treat breast 
cancer2. Additionally, gefitinib can also be employed to 
treat many other tumors, such as lung cancer. Gefitinib 
inhibits EGFR tyrosine kinase by binding to the aden-
osine triphosphate (ATP)-binding site of  the enzyme. 
Therefore, EGFR tyrosine kinase has been widely ac-
cepted as the major target for gefitinib in breast cancer 
treatment. However, a drug always has multiple ther-
apeutic targets and mechanisms, and combination of  
multiple target pathways can facilitate the explanation 
of  therapeutic mechanism. Therefore, searching new 
therapeutic mechanism of  gefitinib towards breast can-
cer will provide the opportunity to completely explain 
the therapeutic mechanism of  gefitinib towards breast 
cancer.
Metabolomics is the scientific study of  chemical pro-
cesses involving small molecules metabolites3. Metab-
olomics study has played a key role in elucidating the 
mechanism of  various cancers. Metabolomics study of  
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colon cancers showed that the elevation of  level of  tau-
rine, isoglutamine, choline, lactate, phenylalanine and 
tyrosine, and the reduction of   lipids and triglycerides 
is closely related with the pathogenesis of  colon cancer 
4. For breast cancer, the alteration of  histidine, acetoac-
etate, glycerol, pyruvate, glycoproteins (N-acetyl), man-
nose, glutamate and phenylalanine has been demon-
strated to be the key factor5.
The present study aims to determine the therapeutic 
mechanism of  gefitinib using targeted metabolomics. 
Materials and methods
The statement of  Ethics
Ethical approval for this study was granted from affil-
iated Yuhuangding hospital, and all enrolled women in 
this study gave the written informed consent.
Study Population
Healthy women (n=56) and women with breast cancer 
(n=60) were enrolled in Affiliated Yuhuangding hospi-
tal, medical college of  Qingdao University from 2012-
2014.  The serum was taken before and after treatment 
with 500 mg/day for 1 months through centrifugation 
(the speed 8,000 g) of  blood. 
Targeted metabolomics analysis of  amino acids 
components
The aliquots (10 uL) of  serum were dropped on the fil-
ter paper, and then filter paper was placed into 96-well 
polypropylene micro titer plates. 100 µL of  methanol 
solution containing isotope labeled amino acid internal 
standards (NSK-A, NSK-B, Cambridge Isotope Labo-
ratories, Andover, USA) was employed to extract the 
samples. Gentle shaking was performed at room tem-
perature for 30 min. After evaporation at 70°C for 40 
min, 60 µL of  3n butanolic-HCL was added for deri-
vatisation at 65°C. After a second evaporation step the 
samples were reconstituted with 150 µL of  the mo-
bile phase (1/1 v/v isopropanol/water) and analyzed 
by flow injection analysis (FIA)-MS/MS using a API 
3200 triple quadrupole mass spectrometer (AB SCIEX, 
Darmstadt, Germany). The mobile phase is 70/30 (v/v) 
acetonitrile/water, and changed flow rate was used as 
followed: 0.01-0.1 min, 0.26 mL/min; 0.11-0.45 min, 
0.02 mL/min; 1-1.2 min, 0.1-0.6 mL/min; 1.2-1.4 min, 
0.6 mL/min; 1.41-2 min, 0.26 mL/min. The following 
mass conditions were used: Curtain gas, 20 psi; Colli-
sion gas, 8 psi; Ionspray voltage, 4500 V; Temperature, 
350oC; Ion source gas (GS) 1 and 2, 35 psi. Neutral loss 
(NL) of  102.1 Da and precursor ion monitoring of  85.1 
Da were used to monitoring the amino acids and their 
corresponding internal standard.
Statistical analysis
The data was given using Prism software (version 4.0; 
GraphPad). Statistical difference was performed using 
one student two-tailed t-test.
Results
The concentration of   amino acids was firstly compared 
between healthy women and women with breast can-
cers. As shown in Figure 1, the concentration of  argi-
nine was 14.7 ± 0.9 uM. 
Figure 1 Arginine significantly decreased in pre-treatment patients with breast cancer.  The concentration of  ar-
ginine in health volunteers (n=56) and patients (n=60) was given in Figure. ****, p<0.0001.
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Compared with the healthy women, the concentra-
tion of  arginine in breast cancer women significantly 
decreased (value= 5.4 ± 0.3, p<0.0001). To show the 
representative capability of   arginine towards the patho-
genesis of  breast cancers, the  receiver operating char-
acteristic (ROC) curve was drawn, and the area under 
the curve (AUC) was calculated to be  0.96 ± 0.02, in-
dicating the high predictive capability of  arginine for 
breast cancer (Figure 2). 
Figure 2 Receiver operating characteristic (ROC) curve to demonstrate the sensitivity and specificity for Arginine 
as the prediction biomarker.
The reversing ability of  gefitinib towards the level of  
arginine was further determined, and 1 month treat-
ment of  gefitinib (500 mg/day) significantly reversed 
the arginine level of  breast cancer patients (p<0.0001) 
(Figure 3). Other amino acids did not changed among 
these three groups (data not shown).
Figure 3 Comparison of  arginine level in serum from pre-treatment and after-treatment patients (n=60). ****, 
p<0.0001.
Discussion
Amino acids are organic compounds that combine to 
form proteins, and amino acids and proteins are the 
building blocks of  life.  Additionally, amino acids are 
important energy source for the body6. The present 
study showed that arginine significantly decreased in 
breast cancer patients in comparison with healthy vol-
unteers. The decrease of  arginine in serum indicated 
possible elevation of  arginine in tumor tissues. Previous 
literature showed that arginine starvation could protect 
breast cancer cells through impairing mitochondrial 
respiratory function7. Therefore, gefitinib-induced  el-
evation of  arginine in serum for gefitinib-treated pa-
tients might indicate the possible therapy role through 
decreasing the arginine level in tumor tissues.
It should be noted previous literature showed that tryp-
tophan is the key native marker in cells to determine the 
level of  metastasis competence in breast cell lines using 
native fluorescence spectroscopy8. However, the pres-
ent study did not detect the alteration of  tryptophan 
in breast cancers, and the reversing effect of  gefitinib 
towards tryptophan. The reason might be the number 
of  patients is not enough, and maybe the in vitro results 
are not easily translated into  in vivo situation. 
In conclusion, the therapy of  Gefitinib towards breast 
cancer through reversing breast cancer biomarker argi-
nine was demonstrated.
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